Brii Biosciences Says Data From Phase 2 Trial of Anti-Hepatitis B Drug 'Encouraging'

MT Newswires Live

May 08

Brii Biosciences' (HKG:2137) said a group of phase 2 trial enrollees of a chronic hepatitis B treatment plan showed immune responsiveness after taking the company's BRII-179 drug, according to a Thursday filing with the Hong Kong bourse.

The data from cohort 4 of the study are "encouraging," Chief Medical Officer David Margolis said during the presentation of data during a congress in Amsterdam, the Netherlands.

The trial assessed the efficacy of the drug, together with a combination of elebsiran and pegylated interferon alpha in patients with chronic hepatitis B, the filing said.

"We saw in target populations that patients who were immune-responsive through pre-treatment with BRII-179 demonstrated a significant advantage in achieving a higher HBsAg seroclearance rate," said Margolis.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2533756799"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533756799\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2533756799?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-08 16:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533756799","market":"hk","top_or_hot":-1,"title":"Brii Biosciences Says Data From Phase 2 Trial of Anti-Hepatitis B Drug 'Encouraging'","media":"MT Newswires Live","content":"<html><body><p> Brii Biosciences' (HKG:2137) said a group of phase 2 trial enrollees of a chronic hepatitis B treatment plan showed immune responsiveness after taking the company's BRII-179 drug, according to a Thursday filing with the Hong Kong bourse.</p><p>The data from cohort 4 of the study are \"encouraging,\" Chief Medical Officer David Margolis said during the presentation of data during a congress in Amsterdam, the Netherlands.</p><p>The trial assessed the efficacy of the drug, together with a combination of elebsiran and pegylated interferon alpha in patients with chronic hepatitis B, the filing said.</p><p>\"We saw in target populations that patients who were immune-responsive through pre-treatment with BRII-179 demonstrated a significant advantage in achieving a higher HBsAg seroclearance rate,\" said Margolis.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Brii Biosciences Says Data From Phase 2 Trial of Anti-Hepatitis B Drug 'Encouraging'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBrii Biosciences Says Data From Phase 2 Trial of Anti-Hepatitis B Drug 'Encouraging'\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-08 16:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Brii Biosciences' (HKG:2137) said a group of phase 2 trial enrollees of a chronic hepatitis B treatment plan showed immune responsiveness after taking the company's BRII-179 drug, according to a Thursday filing with the Hong Kong bourse.</p><p>The data from cohort 4 of the study are \"encouraging,\" Chief Medical Officer David Margolis said during the presentation of data during a congress in Amsterdam, the Netherlands.</p><p>The trial assessed the efficacy of the drug, together with a combination of elebsiran and pegylated interferon alpha in patients with chronic hepatitis B, the filing said.</p><p>\"We saw in target populations that patients who were immune-responsive through pre-treatment with BRII-179 demonstrated a significant advantage in achieving a higher HBsAg seroclearance rate,\" said Margolis.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2533756799","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533756799","pubTimestamp":1746693550,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Brii Biosciences'  said a group of phase 2 trial enrollees of a chronic hepatitis B treatment plan showed immune responsiveness after taking the company's BRII-179 drug, according to a Thursday filing with the Hong Kong bourse.The data from cohort 4 of the study are \"encouraging,\" Chief Medical Officer David Margolis said during the presentation of data during a congress in Amsterdam, the Netherlands.The trial assessed the efficacy of the drug, together with a combination of elebsiran and pegylated interferon alpha in patients with chronic hepatitis B, the filing said.\"We saw in target populations that patients who were immune-responsive through pre-treatment with BRII-179 demonstrated a significant advantage in achieving a higher HBsAg seroclearance rate,\" said Margolis.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02137":"腾盛博药-B","BK1587":"次新股","BK1574":"生物医药B类股"},"translate_title":"Brii Biosciences表示抗乙型肝炎药物2期试验的数据“令人鼓舞”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02137":0.9},"content_text":"Brii Biosciences' (HKG:2137) said a group of phase 2 trial enrollees of a chronic hepatitis B treatment plan showed immune responsiveness after taking the company's BRII-179 drug, according to a Thursday filing with the Hong Kong bourse.The data from cohort 4 of the study are \"encouraging,\" Chief Medical Officer David Margolis said during the presentation of data during a congress in Amsterdam, the Netherlands.The trial assessed the efficacy of the drug, together with a combination of elebsiran and pegylated interferon alpha in patients with chronic hepatitis B, the filing said.\"We saw in target populations that patients who were immune-responsive through pre-treatment with BRII-179 demonstrated a significant advantage in achieving a higher HBsAg seroclearance rate,\" said Margolis.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}